Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Alpha Tau Medical Ltd ( (DRTS) ) is now available.
In the first quarter of 2026, Alpha Tau Medical reported that interim data from its U.S. REGAIN trial in recurrent glioblastoma, as of May 3, showed 100% local disease control and a 67% complete response rate in the first three patients, alongside a favorable safety profile. The company also completed enrollment of 88 patients in its pivotal ReSTART trial for recurrent cutaneous squamous cell carcinoma, its first U.S. pivotal study to reach full enrollment, while maintaining liquidity of $80.2 million to support ongoing trials and commercialization.
The company highlighted growing evidence for Alpha DaRT in pancreatic cancer, including pooled first-in-human data with 100% local disease control presented at Digestive Disease Week 2026 and first pancreatic patients treated in France and Italy under European trials. With FDA approval to expand its IMPACT pancreatic pilot trial and multiple upcoming data and recruitment milestones across glioblastoma, pancreatic cancer, and cutaneous squamous cell carcinoma through late 2026 and early 2027, Alpha Tau is positioning itself as an emerging player in oncology devices with increasing scientific recognition and a clearer regulatory path to potential U.S. market entry.
The most recent analyst rating on (DRTS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and accelerating cash burn), partly offset by a stronger technical setup with the stock trending above major moving averages and positive momentum. Valuation remains constrained by negative earnings and the lack of dividend yield data.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israel-based medical technology company focused on developing Alpha DaRT, an alpha-radiation therapy for solid tumors such as head and neck, cutaneous squamous cell carcinoma, glioblastoma, and pancreatic cancer. The company is advancing multiple clinical programs globally and preparing for commercialization, including after securing marketing approval in Japan for unresectable locally advanced or recurrent head and neck cancer.
Average Trading Volume: 455,656
Technical Sentiment Signal: Buy
Current Market Cap: $911.8M
For detailed information about DRTS stock, go to TipRanks’ Stock Analysis page.